Modern WisdomHealth Hacks Big Pharma Doesn’t Want You To Know - Biohacking Roundtable
CHAPTERS
- 0:00 – 1:41
Peptides as targeted tools: immune support, injury repair, GH stacks
The roundtable opens with each guest sharing how they actually use peptides in real life—less as daily “protocols” and more as situational tools. They cover immune support while traveling, injury-repair staples, and periodic growth-hormone–oriented cycles.
- •Peptides framed as “condiments,” not a permanent everyday regimen
- •Travel immune support: Thymosin Alpha-1
- •Injury repair staples: BPC-157 and TB-500
- •GH-oriented cycles: tesamorelin, ipamorelin, CJC-1295
- •Intranasal cognition/anxiety tools: Cerebrolysin-adjacent style peptides (C-Max/C-Link)
- 1:41 – 3:00
IGF-LR3 vs HGH: benefits, safety, cycling, and side effects
The discussion shifts to IGF-LR3 as an alternative way to pursue some of the benefits people seek from growth hormone. They compare downstream effects, safety profile, impacts on endogenous production, and how users might cycle between approaches.
- •IGF-LR3 positioned as delivering many HGH benefits with fewer downsides
- •Concerns with exogenous HGH: higher glucose, cortisol effects, sleep disruption
- •Cycling strategy: IGF-LR3 for weeks, then shift to GH secretagogue-style support
- •Emphasis on being mindful of maintaining natural GH output in midlife
- •Practical dosing/cycle considerations rather than blanket daily use
- 3:00 – 6:47
Microdosing GLP-1s: inflammation control, “food noise,” and early cancer hypotheses
They introduce GLP-1 microdosing not primarily for weight loss but for inflammation and appetite/food-noise suppression—especially as a travel hack. The panel debates mechanisms, including whether benefits are direct or simply due to reduced food intake.
- •Microdose GLP-1 use framed as anti-inflammatory and appetite-quieting
- •Speculation on cancer risk reduction and the role of inflammation vs less eating
- •“Food noise” reduction used strategically on travel/flight days
- •Anecdotal clinic-level observations from large patient population
- •Acknowledgement that mechanisms and causal pathways remain uncertain
- 6:47 – 14:01
Scientists’ “no-data” health hacks: BioCharger, Tecar therapy, and light/sound entrainment
Chris asks for favorite interventions that feel effective even without strong clinical backing. The conversation becomes a tour through fringe and emerging devices, from BioCharger and Tecar-style tools to vibroacoustic/light-sound systems that induce altered states.
- •BioCharger described (PEMF/RF/“recipes”) with mixed personal experiences
- •Tecar-style ‘WINBACK’ therapy raised as a possible tissue-healing tool
- •RoXiva light/sound entrainment framed as brainwave shifting and deep state change
- •Shiftwave vibration chair mentioned for breathwork and HRV improvements
- •Safe-and-Sound/Polyvagal connections: calming maternal-frequency audio bands
- 14:01 – 20:40
Hyperbaric oxygen + hydrogen: oxygen sessions, baths, inhalation, and ‘selective antioxidants’
They move to more established (HBOT) and semi-established (hydrogen) interventions that many biohackers swear by. The group compares delivery methods (tablets, water, baths, inhalation), plausible mechanisms, and how these intersect with training recovery and hormesis.
- •HBOT (hard shell ~2.2 ATA) described as a powerful energy/clarity booster
- •Hydrogen delivery comparison: tablets, flasks, baths, inhalation masks
- •Proposed mechanism: hydrogen as a selective antioxidant that may not blunt adaptation
- •Cold plunge ‘blunting gains’ nuance: time/temperature threshold matters
- •Practical biohacker tradeoffs: relaxation benefits vs placebo/confounding (e.g., hot tub)
- 20:40 – 24:02
Sauna, heat shock proteins, and fertility tradeoffs (plus ‘ice balls’)
The panel digs into what it really takes to trigger heat shock proteins, including temperature/time and personal factors like leanness and movement in the sauna. They also discuss head protection, potential dementia concerns, and fertility impacts from hot water exposure.
- •Heat shock proteins may require hotter/longer sauna exposure than many do
- •Movement in sauna can elevate internal temperature faster
- •Head/brain overheating concerns; wool caps as mitigation
- •Fertility: hot tubs/jacuzzis may be worse than sauna due to direct heat transfer
- •Alternatives to sauna for HSPs: resistance training, heat exercise, even cold exposure
- 24:02 – 27:21
Resonance breathing as ‘trait’ training: HRV lamps and subconscious breathing control
Chris shares enthusiasm for resonance breathing devices that entrain breathing to maximize HRV. Ben explains the physiology and why ~5.5 seconds in/out tends to be a human sweet spot, and they discuss how longer practice drives durable ‘trait’ changes.
- •Om.Health lamp uses HRV sensing + vibration cues to guide breathing rate
- •Resonance breathing often peaks HRV around ~5.5s inhale/~5.5s exhale
- •“State vs trait” framing: longer sessions translate into lasting autonomic benefits
- •Tools to prevent ‘email apnea’ and sustain parasympathetic tone during stress
- •Simple DIY predecessor: ‘Clock and Bell’ style audio pacing cues
- 27:21 – 36:18
MUSE stem cells: engraftment, BBB penetration, and state-by-state access
A major segment focuses on MUSE stem cells as a potentially breakthrough subset with stronger durability and engraftment than typical MSCs. They highlight claimed safety advantages, neurological applications, and how legal frameworks in different US states affect access.
- •MUSE = Multi-lineage Stress Enduring cells; framed as ‘super soldier’ stem cells
- •Claims: higher engraftment (~30%), faster engraftment, room-temp durability
- •Ability to cross blood-brain barrier; examples discussed: stroke tagging, neuro repair
- •Tumorigenic concerns with stem cells and why MUSE is pitched as safer
- •Access landscape: right-to-try/state laws (TX/FL/TN/UT) vs FDA approval status
- 36:18 – 53:47
GLP-1s at scale: sarcopenia/osteoporosis risk, dosing problems, and desire suppression
They return to GLP-1s as a society-wide intervention, focusing on second-order consequences: muscle loss risk, bone health, and the problem of high standardized doses driven by trials and insurance. They also explore emerging reports of libido/mood changes tied to dopamine reward pathways.
- •Rapid weight loss at population scale could trade obesity for sarcopenia/frailty
- •Insurance and trial-driven dosing pushes patients toward higher-than-needed doses
- •Muscle loss may reflect reduced intake/training capacity; DEXA limitations discussed
- •Sex-drive divergence: possible increases in men vs decreases in women (emerging data)
- •Broader ‘desire suppression’ hypothesis: reward pathways, anhedonia, mood impacts
- 53:47 – 1:12:43
Testosterone stigma, ‘replacement vs enhancement,’ and why low T is a health risk
A long arc examines why testosterone became culturally and medically demonized, tracing myths back to flawed early prostate-cancer dogma and later parallels with women’s hormones. They argue low testosterone carries real disease risk, and that individualized treatment should be separated from performance-enhancing abuse.
- •Origin story: early prostate cancer fears and how dogma persisted for decades
- •Saturation/receptor model: more nuanced risk than ‘testosterone causes cancer’
- •Replacement vs supraphysiologic enhancement as the core misunderstanding
- •War fighters/screening: performance and health implications of untreated hypogonadism
- •Individual variability: receptors (e.g., CAG repeats), SHBG/free vs total testosterone
- 1:12:43 – 1:29:37
The peptide crackdown: FDA hearings, gray markets, patents, and ‘right to try’
Brigham explains the regulatory conflict over compounded peptides, describing an abrupt “naughty list,” FOIA struggles, and a high-stakes FDA hearing focused on safety rather than efficacy. The group expands into a broader debate over medical freedom, clinician autonomy, and the unintended creation of dangerous gray markets.
- •FDA restriction of compounded peptides framed as sudden and poorly justified
- •Safety emphasis: retrospective analyses and low adverse-event counts presented
- •Unintended consequence: shift toward unregulated APIs and contamination incidents
- •Patent incentives: why nature-identical peptides don’t attract costly RCT pipelines
- •Medical freedom vs protection: clinician-supervised ‘right to try’ as a proposed path
- 1:29:37 – 1:36:15
Plasmapheresis for longevity/toxins: ‘oil change’ claims, immune dip, and practicality
They explore plasmapheresis and related filtration protocols as an emerging longevity and detox-style intervention. The conversation covers mechanisms, specialized filters (microplastics/other targets), the short-term immune suppression critique, and why cost/access remain major barriers.
- •Plasmapheresis explained: plasma removal + replacement (often albumin)
- •Specialized filtration media discussed for different targets (e.g., microplastics)
- •Critiques addressed: catheter risks and ~24-hour immune suppression window
- •Anecdotes: inflammation reduction and sleep improvements reported post-procedure
- •Constraints: expensive, time-intensive, and not easily ‘democratized’ yet
- 1:36:15 – 1:44:44
Cost-free longevity: lifting, VO2 bursts, walking speed, and ‘healthspan realism’
Chris asks for the most impactful interventions that don’t require expensive gear or clinics. They emphasize resistance training, simple VO2-improving sprints, and brisk walking cadence, while reframing longevity as ‘healthspan’ and capability rather than immortality.
- •Strength training prioritized to reduce frailty risk and preserve function
- •VO2 max improved with brief 10–20s bursts multiple times per week
- •Walking speed/cadence highlighted as a surprisingly strong longevity correlate
- •Healthspan vs lifespan: focus on quality of time rather than escaping death
- •Relationships and purpose acknowledged as major (but less ‘sexy’) drivers
- 1:44:44 – 2:10:51
Protein, fiber, diet choices, eating speed, and fasting: what’s hype vs useful
The panel debates ‘proteinmaxxing,’ fiber’s rising popularity, and individualized gut tolerance. They connect eating speed to endogenous GLP-1 release and then tackle fasting—what it can and can’t do versus simple calorie restriction, including sex-specific cautions.
- •Protein ‘sweet spot’ discussed around ~1.2–1.6 g/kg (context-dependent)
- •Fiber benefits vs GI downsides; FODMAP/SIBO and fermentable fiber variability
- •Food matrix idea: foods behave differently than isolated macros/supplements
- •Eating slower may increase natural GLP-1 response and satiety
- •Fasting: little advantage vs calorie restriction unless >18h; women-specific considerations
- 2:10:51 – 2:50:37
Where people waste money: imaging vs labs, early cancer screening, microplastics, EMFs, air
They close on diagnostics and environmental risks—what’s overemphasized, what’s underused, and where the next ‘big’ health attention may go. Topics include heart imaging vs lipid panels, full-body MRI tradeoffs, microplastics measurement pitfalls, EMF mitigation, and home air-quality system design.
- •Lipid panels alone can mislead; CT angiography/Cleerly-style imaging discussed
- •Full-body MRI as early detection tool—useful but can create anxiety/over-treatment
- •Early multi-cancer screening (e.g., GRAIL/Galleri) argued as valuable with nuance
- •Microplastics: major exposure via food packaging; lab glove contamination confounds
- •EMFs and air quality: proximity matters; bedroom prioritized; HVAC needs filter + scrub + fresh-air recirculation
